Oxidative stress and inflammation are important pathogenetic mechanisms in amyotrophic lateral sclerosis (ALS). Nuclear erythroid 2Yrelated factor 2 (Nrf2) is a basic region leucine-zipper transcription factor that binds to the antioxidant response element, thereby regulating the expression of many genes that are involved in cellular antioxidant and anti-inflammatory defense. Under normal conditions, Nrf2 activation is inhibited by Kelch-like ECH-associated protein 1 (Keap1). We investigated the potential involvement of the Nrf2/antioxidant response element signaling pathway in the selective degeneration of motor neurons in ALS. Nrf2 and Keap1 expression was analyzed in primary motor cortex and spinal cord postmortem tissue samples from ALS patients and controls by in situ hybridization histochemistry, quantitative real-time polymerase chain reaction, immunohistochemistry, and Western blot analysis. In ALS samples, there was a reduction of Nrf2 mRNA and protein expression in neurons, whereas Keap1 mRNA expression was increased in the motor cortex. These results suggest that alterations in this signaling cascade occur in motor neurons in ALS and that they may contribute to chronic motor neuron degeneration.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset motor neuron disorder with an average survival of 3 to 5 years. Patients develop rapidly progressive paralysis due to degeneration of motor neurons in the primary motor cortex, brainstem, and spinal cord. Oxidative damage seems to play a major role in the pathogenesis of chronic motor neuron death based on the following lines of evidence: i) markers of oxidative damage of proteins, lipids, and DNA are elevated in brain and spinal cord in both mutant superoxide dismutase 1 (SOD1) ALS-mouse models (1) and in human familial and sporadic ALS (2Y6), and ii) a large number of antioxidant compounds have been shown to be neuroprotective in ALS mouse models (7Y10).
A major transcriptional modulator of the cellular antioxidant response is the basic region leucine-zipper transcription factor nuclear factor erythroid 2-related factor 2 (NRf2). After activation and translocation to the nucleus, NRf2 binds to the antioxidant response element (ARE), a regulatory enhancer region within gene promoters, thus regulating the expression of more than 200 genes involved in the cellular antioxidant and anti-inflammatory defense. Among these are the classical phase 2 detoxification enzymes such as NAD(P)H quinone oxidoreductase and glutathione, enzymes that are necessary for glutathione biosynthesis, extracellular superoxide dismutase, glutamate-6-phosphatedehydrogenase, heat shock proteins, and ferritin. Furthermore, pro-inflammatory and anti-inflammatory enzymes such as cyclooxygenase 2, inducible nitric oxide synthase, and heme oxygenase-1 are also regulated in this manner (11, 12) . In addition to its role in inducing ARE-dependent gene transcription, Nrf2 also has direct cytoprotective effects via the inhibition of Fas-triggered apoptotic pathways (13) . Neuronal and astroglial cells from Nrf2 knockout mice are more vulnerable to oxidative stress than wild-type cells in vitro, and overexpression of Nrf2 increases resistance against oxidative and excitotoxic stimuli (12, 14, 15) .
The translocation of Nrf2 to the nucleus is inhibited by the actin-bound cytoskeletal zinc metalloprotein Kelch-like ECH-associated protein1 (Keap1), which interacts with Nrf2 and leads to its sequestration and subsequent degradation by the ubiquitin-proteasome system (16Y18). Decreased KeapNrf2 binding (via oxidation of sulfhydryl groups or phosphorylation) results in intranuclear shuttling of Nrf2 and subsequent transcription of ARE-driven genes (11, 19Y21) . Therefore, Keap1 and Nrf2 constitute a mechanism by which cells can sense damage caused by free oxygen radicals (16) . Furthermore, the antioxidant effects of Nrf2 activation inversely correlate with an inflammatory response (22) .
Here, we investigated mRNA and protein expression of Nrf2 and its endogenous inhibitor Keap1 in the primary motor cortex and the spinal cord of postmortem tissue samples from ALS patients and controls to assess the involvement of this signaling cascade in the molecular pathogenesis of motor neuron death in ALS.
MATERIALS AND METHODS

Human Postmortem Tissue Samples
Postmortem brain and lumbar spinal cord (L2-4) specimens from 5 ALS patients from between 61 and 82 years (mean age, 67 years; 3 males, 2 females) were analyzed. The ALS patients had a definite diagnosis based on the El Escorial criteria; that is, they showed signs of upper and lower motor neuron involvement in 3 body regions (23) . Similar samples from 5 patients between 65 and 84 years of age (mean age, 69 years; 3 males, 2 females) with no evidence of neurological or psychiatric disease from autopsies from the neuropathology department were used as controls (Table) . The postmortem intervals ranged from 8 to 32 hours. The primary motor cortex (Area 4 according to the nomenclature of Brodmann) was first identified macroscopically. Brains and spinal cords were cut into coronal slices of 1-cm thickness and rapidly frozen on dry ice. Cryostat sections of brain specimens were stained with Nissl stain, and their cytoarchitecture was studied histologically by a neuropathologist to confirm that they were from the primary motor cortex. Giant Betz cells were clearly distinguishable in 2 of 5 ALS specimens; in the 3 other samples, there was a loss of Betz cells in the precentral gyrus. Twentymicrometer-thick sections of the precentral gyrus and lumbar spinal cord were cut on a cryostat, thaw-mounted onto poly-L-lysine-coated slides, fixed for 5 minutes in 4% phosphatebuffered paraformaldehyde, and stored in 96% ethanol at 4-C until use. Nrf2 and Keap1 expression in brain and spinal cord samples were studied at the mRNA and protein levels.
In Situ Hybridization Histochemistry
In situ hybridization histochemistry was performed as previously described (24, 25) . Oligonucleotide probes (40Y45 mers) complementary to coding parts of the cDNAs (Keap1: 3 ¶ TCG GAT GGT GTT CAT TGC TGT GAT CAT TCG CCA CTC GTT CCT CTC; Nrf2: 5 ¶ CAGGGGCTACCT GAGCAACAGAAGTTTCAGGTGACTGAGCCTG) were synthesized (MWG Biotech, Ebersberg, Germany) and 3 ¶-end labeled with >-33P-dATP (Perkin Elmer, Zaventem, Belgium). Only labels between 250,000 and 350,000 cpm per microliter of the eluate were used for experiments. For each oligonucleotide probe, tissue sections were processed in parallel to obtain x-ray-and emulsion-dipped autoradiograms in adjacent slices. Slides were hybridized for 24 hours at 42-C with labeled probe diluted in hybridization buffer (50% formamide, 4Â SSC, 5Â Denhardt_s solution, 10% dextran sulfate) to a final concentration of 0.07 pmol/ml. After washing in 1x SSC at 56-C for 30 minutes, neighboring sections were either exposed to Biomax x-ray film (Kodak, Stuttgart, Germany) for 4 weeks or dipped in NTB 2 nuclear track emulsion (Kodak). Dipped sections were counterstained with 0.05% thionin, dehydrated, and coverslipped. For negative controls, a 100-fold excess of nonlabeled oligonucleotides was added to the radioactive probe and applied to the adjacent section, leading to a complete suppression of the signal.
Semiquantitative analysis of film autoradiograms of the primary motor cortex (n = 5 in each group) was performed as previously described (24, 26) : Optical density readings were taken in vertical strips 0.5 mm wide across the full thickness of the cortex of area 4 in 3 regions of each section. Optical densities were determined for the thickness of each cortical layer separately by matching the autoradiogram readings to digitized images of the adjacent Nissl-stained sections. Optical density over white matter more than 3 mm deep to overlaying cortex was used for background subtraction. Absolute values of radioactivity were determined from 14C plastic standards (Amersham, Freiburg, Germany) on the same sheet of film (Image J software). Quantified hybridization signals for the patient and the control group were compared using the Student t-test.
Cellular expression patterns of the mRNA transcripts were determined microscopically throughout the cortical layers by classifying the amount of silver grains over motor neurons (identified via Nissl counterstaining) in the ventral horn and in layers III and V of Brodmann area 4 as strong, moderate, or weak according to a visual analog scale. For the amyotrophic lateral sclerosis (ALS) cases, the region of disease onset and duration of disease are also indicated. Lower motor neuron (LMN). ALS cases 1 to 3 and control cases 1 to 3 were used for reverse transcriptase polymerase chain reaction and Western blot experiments of total spinal cord homogenates and for immunohistochemistry. ALS cases 1 to 5 and control cases 1 to 5 were used for in situ hybridization histochemistry. NA = not applicable.
M, male; F, female; NA, not available.
Quantitative Real-Time Polymerase Chain Reaction
For quantitative real-time polymerase chain reaction (PCR) analysis, total RNA from motor cortex and spinal cord (ventral horn) specimens of ALS patients and controls (n = 3 each) were extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and subsequent purification by the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA integrity was assessed by calculation of RNA integrity numbers using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Immunohistochemistry
For immunohistochemistry, additional fresh-frozen brain and spinal cord sections were identically prepared, fixed in ice-cold acetone for 15 minutes, and rinsed in 1Â phosphate-buffered saline (PBS; n = 3 for patients and controls). Endogenous peroxidase was blocked with 3% hydrogen peroxide and 10% methanol in 1Â PBS. After preincubation with 1% bovine serum albumin (BSA) in 1Â PBS/0.3% Triton X-100 for 30 minutes at room temperature, sections were incubated with a rabbit polyclonal antibody directed against Nrf2 (Abcam, Cambridge, UK) or a rabbit polyclonal antibody directed against Keap1 (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4-C, followed the next day by an incubation with biotinylated rabbitYantimouse IgG (1:300 in PBS; DAKO, Glostrup, Denmark) and a streptavidin-biotin-horseradish peroxidase complex (Vector Laboratories, Burlingame, CA; 1:100 in PBS) for 30 minutes each at room temperature. The final enzymatic reaction was performed for 5 minutes using 0.01% H 2 O 2 as substrate and 0.1% diaminobenzidine (Dako Cytomation, Glostrup, Denmark) as chromogen in 0.05M PBS.
Immunofluorescence
Double immunofluorescence was performed to study astrocytic colocalization of Nrf2. Endogenous peroxidase was blocked with 3% hydrogen peroxide and 10% methanol in 1Â PBS. After preincubation with 1% BSA in 1Â PBS/ 0.3% Triton X-100 for 30 
Western Blot Analysis
For Western blot analysis, motor cortex and spinal cord protein homogenates (n = 3 for patients and controls; 80 Kg of protein) were electrophoresed on sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions and transferred to nitrocellulose membranes (Amersham, Piscataway, NJ) by standard procedures. Membranes were blocked with 5% nonfat dry milk and then incubated with rabbit polyclonal antibodies anti-Nrf2, rabbit polyclonal anti-Keap1 (both from Santa Cruz Biotechnology), and rabbit polyclonal anti-beta actin (Abcam). After washing, the membranes were incubated with the appropriate horseradish peroxidaseYconjugated secondary antibodies. Antigen-antibody complexes were visualized by enhanced chemiluminescence detection (Amersham, Piscataway, NJ). Membranes were stripped and reprobed as needed. Quantification was done by densitometry using Image J software; values were normalized to beta actin.
RESULTS
Nrf2 mRNA Is Reduced in ALS Motor Cortex and Spinal Cord
Expression of Nrf2 and Keap1 mRNA was first studied by in situ hybridization in the primary motor cortex and spinal cord. In the primary motor cortex, densitometric quantification of film autoradiograms was performed. mRNA expression of both transcripts was detected throughout the cortical layers, with results shown in Figures 1AYD ; results of densitometry analysis are shown in Figures 1A, E, F . There was reduced mRNA expression of Nrf2 throughout the layers in ALS tissues with a signal below 80 nCi/g, whereas values between 120 and 150 nCi/g were measured in control sections (p G 0.005; Fig. 1A ). There was a trend toward higher signal intensity for Keap1 in layers III to V in ALS motor cortex with labels higher than 100 nCi/g in patients and lower than 70 nCi/g in controls.
To study the cellular localization of Nrf2 and Keap1 transcripts, we performed liquid emulsion autoradiography (Fig. 1B) . In the motor cortex, the cellular expression of Nrf2 and Keap1 seemed predominantly in neurons in the Nisslcounterstained slides. In the large pyramidal cells of layers III and V, labeling was moderate in most cells in the control sections and much weaker in the ALS patient samples. In emulsion-dipped slides of the spinal cord, RNAs were displayed in a homogenous pattern in the ventral and dorsal horn with a predominant neuronal expression. Both transcripts were present in large motoneurons of the ventral horn. Control spinal cord sections displayed a similar staining pattern for both mRNAs but with moderate to strong Nrf2 mRNA expression in motor neurons; Nrf2 mRNA expression was weak to moderate in the ALS patient samples (Fig. 1B) . The addition of 100-fold excess of nonlabeled oligonucleotides reduced the hybridization signals (Fig. 1A, insets) .
A significant reduction of Nrf2 mRNA in both ALS motor cortex (1.5-fold) and ventral horn (1.4-fold) was also identified by quantitative real-time PCR (p G 0.01; Fig. 2A ).
For Keap1, there was a significant increase of mRNA expression in ALS motor cortex tissues (1.9 fold; p G 0.05), whereas no significant differences were found in ventral horn homogenates (Fig. 2B) . 
Protein Expression of Nrf2 is Lower in ALS Than in Control Postmortem Tissue
We next investigated Nrf2 and Keap1 protein expression. Immunostaining showed a general reduced cellular Nrf2 protein expression in both the ventral horn and the primary motor cortex in ALS tissue. In control motor cortex and spinal cord, Nrf2 expression seemed to be predominantly in the cytoplasm, and no nuclear labeling could be observed. In ALS samples, the immunohistochemistry labeling was less intense and more diffuse throughout the cells; this might indicate some translocation of Nrf2 to the nucleus (Fig. 3A) .
Immunofluorescent staining of primary motor cortex sections with the astrocyte marker GFAP showed increased astrocytosis in the ALS sections (Fig. 4B) and some colocalization of Nrf2 and GFAP, indicating astrocytic expression; however, most of the Nrf2 signal was detected in pyramidal cells.
In Western blots of tissue homogenates of the primary motor cortex and of the ventral horn, lower protein levels of Nrf2 were also detected in ALS compared with control tissue specimens. These differences were significant in the densitometric quantification (1.5-fold in the motor cortex, p G 0.05; 1.3-fold in the spinal cord, p G 0.001) ( Fig. 3B) . For Keap1, however, immunohistochemistry and Western blot revealed similar protein expression levels (Fig. 5) in ALS patients and controls in both motor cortex and spinal cord.
DISCUSSION
We investigated, for the first time, mRNA and protein expression of the transcription factor Nrf2 and its endogenous inhibitor Keap1 in brain and spinal cord specimens of ALS patients and controls. The study was undertaken to determine whether molecular differences within this signaling cascade could play a role in the oxidative stress-related pathogenesis of this chronic neurodegenerative disease. We found reduced neuronal mRNA levels of the transcription factor Nrf2 both in motor neurons of the primary motor cortex and the ventral horn and correspondingly decreased Nrf2 protein expression. Although the decreased Nrf2 signal in the analysis of film autoradiograms and in RT-PCR and Western blot could be due to neuronal loss in these areas, assessment of liquid emulsion autoradiography and immunostaining indicated a reduction of the Nrf2-mRNA and protein signal at individual cell level. As the transcriptional activity of Nrf2 decreases physiologically with age in rats (27) , the reduced Nrf2 mRNA and protein levels in ALS might have been age dependent. Because we used agematched control tissue samples, however, the observed loss in Nrf2 mRNA and protein expression cannot simply be explained by age effects.
By contrast, for Keap1, the endogenous inhibitor of Nrf2, slightly increased mRNA levels were observed only in the primary motor cortex but not in the spinal cord; at the protein level, Keap1 expression in motor cortex and spinal cord was not different from that in controls. Because the ALS samples are from end-stage disease, however, we cannot rule out a role for Keap1 in motor neuron death in ALS; that is, the expression could have been altered in presymptomatic or early symptomatic stages of the disease.
Nrf2 protein expression has previously been studied in postmortem brain samples in other neurodegenerative diseases such as Alzheimer disease (AD), Lewy body variant of AD and Parkinson disease (21) . Nrf2 was localized mainly in neuron cytoplasm in AD and Lewy body variant of AD hippocampi and enthorhinal cortex. It was therefore concluded that nuclear translocation of Nrf2 is impaired and that the cellular defense against oxidative stress is reduced due to a dysfunction in the Nrf2 pathway (21) . By contrast in the Parkinson disease cases, nuclear Nrf2 levels in the substantia nigra were increased, which could be interpreted as an appropriate neuronal response to oxidative stimuli (21) .
Although the present study is the first to explore human ALS postmortem tissue, several studies have been done in SOD1 transgenic ALS animal and in vitro models. Corresponding to our findings, a reduction of Nrf2 was detected in primary motor neuron cultures generated from G93A transgenic mice. These cells showed increased vulnerability to neuronal apoptosis induced by nerve growth factor (28) . Similarly, microarray analysis revealed downregulation of genes regulated by Nrf2 in the motor neuron-like Nsc34 cell line stably transfected with mutant SOD1, and it was concluded that compounds stimulating this pathway could be of therapeutic value in ALS (29) . In contrast, increased astrocytic Nrf2 levels were observed in a rat model of ALS beginning at symptom onset and persisting until end stage. The authors concluded that this could be an attempt to counteract motor neuron death (30) . In our study, we also detected increased astrocytosis in ALS tissues and some astrocytic localization of Nrf2 but an overall decreased Nrf2 protein expression compared with control specimens. A different approach to study activation of Nrf2-ARE signaling in ALS mice was used by Kraft et al; they crossbred ALS mutant mice with an ARE reporter mouse so that ARE activation could be directly measured via induction of AREdriven human placental alkaline phosphatase activity. In this model, early and intense Nrf2 activation was seen in skeletal muscles. Comparably less activation occurring only after symptom onset was observed in spinal cord motor neurons and astrocytes (31) .
Although mutant SOD1 models reproduce many features of the pathophysiology of familial ALS, no ideal model of sporadic ALS exists to date. The fact that we could not detect Nrf2 activation in postmortem ALS tissue, in contrast to the animal models, could point to different pathogenetic mechanisms of motor neuron degeneration. One recent example is the expression of abnormal variants of the DNA-binding protein TDP-43 (TAR DNA binding protein j43), which is presumed to have a role in transcriptional regulation in sporadic and nonYmutant-SOD1-dependent familial ALS but not in postmortem tissue of patients with SOD1 mutations or in mutant SOD1 mice (32) . The fact that many compounds have been shown to exert neuroprotective effects in animal models but failed in clinical trials also raises concerns about the translation of findings in G93A mice into patients. On the other hand, a limitation of postmortem studies is that they are performed at the terminal stage of ALS. The Nrf2 reduction that we observed therefore does not exclude activation of the Nrf2 pathway during the onset or early symptomatic stages of the disease.
In summary, we found decreased mRNA and protein expression of the transcription factor Nrf2 in motor neurons in motor cortex and spinal cord of ALS patients. This could account for an impaired capacity of these cells to counteract oxidative stress and may be involved in motor neuron death.
